Skye Bioscience (SKYE) Operating Leases (2021 - 2025)
Skye Bioscience (SKYE) posted quarterly Operating Leases of $83999.0 for Q4 2025, down 69.25% year-over-year from $273162.0 in Q4 2024, and down 30.12% quarter-over-quarter from $120207.0 in Q3 2025.
Skye Bioscience (SKYE) Operating Leases (2021 - 2025) Analysis & Trends
Skye Bioscience (SKYE) has reported Operating Leases for 5 consecutive years, with $83999.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Leases fell 69.25% year-over-year to $83999.0; the TTM figure through Dec 2025 stood at $83999.0 (down 69.25% YoY), while the FY2025 annual figure was $83999.0, down 69.25% from the prior year.
- Operating Leases retreated to $83999.0 in Q4 2025 per SKYE's latest filing, from $120207.0 in the prior quarter.
- Across five years, Operating Leases topped out at $274040.0 in Q2 2023 and bottomed at $55906.0 in Q1 2022.
- Historically, Operating Leases has averaged $147266.1 across 5 years, with a median of $125628.5 in 2022.
- Annual changes were most pronounced in 2023 — Operating Leases jumped 209.11% — and 2025, when it slumped 69.25%.
- Skye Bioscience's Operating Leases stood at $78700.0 in 2021, then changed by 0.0% to $78700.0 in 2022, then surged by 209.11% to $243268.0 in 2023, then grew by 12.29% to $273162.0 in 2024, then plunged by 69.25% to $83999.0 in 2025.
- Business Quant data shows SKYE's Operating Leases at $83999.0 in Q4 2025, $120207.0 in Q3 2025, and $172494.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 83,999.00 |
| Sep 30, 2025 | 120,207.00 |
| Jun 30, 2025 | 172,494.00 |
| Mar 31, 2025 | 223,466.00 |
| Dec 31, 2024 | 273,162.00 |
| Sep 30, 2024 | 108,062.00 |
| Jun 30, 2024 | 129,907.00 |
| Mar 31, 2024 | 150,953.00 |
| Dec 31, 2023 | 243,268.00 |
| Sep 30, 2023 | 190,510.00 |
| Jun 30, 2023 | 274,040.00 |
| Mar 31, 2023 | 81,318.00 |
| Dec 31, 2022 | 78,700.00 |
| Sep 30, 2022 | 100,583.00 |
| Jun 30, 2022 | 121,350.00 |
| Mar 31, 2022 | 55,906.00 |
| Dec 31, 2021 | 78,700.00 |
| Sep 30, 2021 | 164,164.00 |